Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Tailored Antiplatelet Therapy Following PCI (TAILOR-PCI)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by Mayo Clinic
Sponsor:
Collaborators:
Spartan Bioscience Inc.
Applied Health Research Centre
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Naveen L. Pereira, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01742117
First received: December 3, 2012
Last updated: June 17, 2016
Last verified: June 2016
History of Changes

December 3, 2012
June 17, 2016
May 2013
September 2019   (final data collection date for primary outcome measure)
Occurrence of the a major adverse cardiovascular event (MACE) [ Time Frame: Randomization, one year after percutaneous coronary intervention (PCI) ] [ Designated as safety issue: Yes ]
MACE will include non-fatal myocardial infarction, non-fatal stroke, cardiovascular mortality, severe recurrent ischemia, and stent thrombosis
Time to occurrence of the composite endpoint of a major adverse cardiovascular event (MACE) [ Time Frame: Randomization, one year after percutaneous coronary intervention (PCI) ] [ Designated as safety issue: Yes ]
MACE will include non-fatal myocardial infarction, non-fatal stroke, cardiovascular mortality, severe recurrent ischemia, and stent thrombosis
Complete list of historical versions of study NCT01742117 on ClinicalTrials.gov Archive Site
Number of subjects with reduced function CYP2C19 allele(s) who have major or minor bleeding [ Time Frame: One year after PCI ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Tailored Antiplatelet Therapy Following PCI
Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI)
Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some studies have suggested that patients who have a certain genetic liver enzyme abnormality (known as cytochrome P450 2C19 [CYP2C19] *2 or *3 allele) may have a reduced ability to activate clopidogrel, and therefore may have a lowered response to clopidogrel. It is thought that perhaps people who have a coronary stent procedure may have this genetic liver enzyme abnormality. There is a research genetic test available to determine whether or not someone has this genetic liver enzyme abnormality. Ticagrelor, is a newer anti-platelet drug that is not dependent on the CYP2C19 liver enzyme for its activation and hence in poor clopidogrel metabolizers, alternative drugs like Ticagrelor have been recommended for use as an anti-platelet agent after PCI. The purpose of this study is to determine if genetic testing can identify the best anti-platelet therapy, for patients who undergo a coronary stent placement and do not activate clopidogrel very well.
TAILOR-PCI is a multi-site, open label, prospective, randomized trial testing the hypothesis that after percutaneous coronary intervention (PCI), using a genotyping strategy ticagrelor 90 mg twice per day is superior to clopidogrel 75 mg per day in reducing a composite endpoint of major adverse cardiovascular events (MACE), i.e., non-fatal myocardial infarction, non-fatal stroke, severe recurrent ischemia, cardiovascular (CV) death, and stent thrombosis (primary endpoints) in CYP2C19 reduced function allele patients. Patients who undergo PCI will be randomized to a conventional therapy arm (i.e., to receive clopidogrel 75 mg once daily without prospective genotyping guidance) versus a prospective CYP2C19 genotype-based anti-platelet therapy approach (ticagrelor 90 mg bid in CYP2C19 *2 or *3 reduced function allele patients, clopidogrel 75 mg once daily in non-*2 or -*3 CYP2C19 patients). Buccal swabs will be obtained for those subjects randomized to the prospective genotyping arm. All subjects will have a blood sample drawn for DNA analysis but genotyping using these DNA samples will be performed only after completion of the duration of anti-platelet therapy (i.e., after one year). The primary endpoints will be assessed prospectively and will be compared between the conventional arm and the prospective genotyping arm among those identified as reduced function CYP2C19 allele carriers according to the 1-year genotype results.
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Coronary Artery Disease
  • Acute Coronary Syndrome
  • Stenosis
  • Drug: Clopidogrel
    Subjects will receive Clopidogrel, one 75 mg tablet per day by mouth for one year.
    Other Name: Plavix
  • Drug: Ticagrelor
    Subjects will receive Ticagrelor, one 90 mg tablet twice per day by mouth.
    Other Name: Brilinta
  • Genetic: Retrospective Genotype testing
    Mayo Clinic will use ABI TaqMan assay of three variants in the CYP2C10 gene: *2, *3 and *17
  • Genetic: Prospective Genotype testing
    Rapid turnaround Spartan^TM Bioscience in vitro diagnostic assay for analysis of three variants in the CYP2C19 gene: *2, *3 and *17
  • Active Comparator: Clopidogrel then Retrospective Genotyping
    Standard clinical practice of clopidogrel 75 mg daily for one year following PCI. DNA samples taken at baseline will be frozen, then at 12 months will be genotype tested to determine the *2 & *3 reduced function or wild type allele status.
    Interventions:
    • Drug: Clopidogrel
    • Genetic: Retrospective Genotype testing
  • Active Comparator: Prospective Genotyping - Clopidogrel
    Patients with the wild type CYP2C19 allele (based on prospective genotype testing) will be assigned to receive a clopidogrel 75mg tablet daily for one year following PCI.
    Interventions:
    • Drug: Clopidogrel
    • Genetic: Prospective Genotype testing
  • Active Comparator: Prospective Genotyping - Ticagrelor
    Patients with the CYP2C19 heterozygous and homozygous *2 and *3 reduced function allele (based on prospective genotype testing) will be assigned to receive a ticagrelor 90 mg tablet twice per day for one year following PCI.
    Interventions:
    • Drug: Ticagrelor
    • Genetic: Prospective Genotype testing
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
5270
March 2020
September 2019   (final data collection date for primary outcome measure)

Inclusion

  • Patient >18 years of age
  • Patient presents with acute coronary syndrome (ACS) or stable coronary artery disease (CAD)
  • Patient is eligible for PCI
  • Patient is willing and able to provide informed written consent

5.3 Exclusion

  • Patient not able to receive 12 months of dual anti-platelet therapy
  • Failure of index PCI
  • Patient or physician refusal to enroll in the study
  • Patient with known CYP2C19 genotype prior to randomization
  • Planned revascularization of any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure
  • Anticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up period, example for elective surgery
  • Serum creatinine >2.5 mg/dL within 7 days of index procedure
  • Platelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index procedure.
  • History of intracranial hemorrhage
  • Known hypersensitivity to clopidogrel or ticagrelor or any of its components
  • Patient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint
  • Patient previously enrolled in this study
  • Patient is pregnant, lactating, or planning to become pregnant within 12 months
  • Patient has received an organ transplant or is on a waiting list for an organ transplant
  • Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the procedure
  • Patient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous, etc.)
  • Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor)
  • Concomitant use of simvastatin/lovastatin > 40 mg qd
  • Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine)
  • Non-cardiac condition limiting life expectancy to less than one year, per physician judgment (e.g. cancer)
  • Known history of severe hepatic impairment
  • Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
  • Patient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding
  • Inability to take aspirin at a dosage of 100 mg or less
  • Current substance abuse (e.g., alcohol, cocaine, heroin, etc.)
Both
18 Years and older   (Adult, Senior)
No
Contact: Monica Olson 507-255-2649 rstTAILORPCI@mayo.edu
United States,   Canada,   Korea, Republic of
 
NCT01742117
11-006837
Yes
Not Provided
Not Provided
Naveen L. Pereira, Mayo Clinic
Mayo Clinic
  • Spartan Bioscience Inc.
  • Applied Health Research Centre
  • National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Naveen Pereira, MD Mayo Clinic
Principal Investigator: Michael E Farkouh, MD Toronto General Hospital
Principal Investigator: Kent R Bailey, PhD Mayo Clinic
Mayo Clinic
June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP